Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma
Article first published online: 7 AUG 2013
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
Journal of Cutaneous Pathology
Volume 40, Issue 10, pages 884–886, October 2013
How to Cite
Bilateral areolar leiomyomas in a patient undergoing BRAF inhibition therapy for melanoma., , , , , , .
- Issue published online: 17 SEP 2013
- Article first published online: 7 AUG 2013
- Accepted manuscript online: 26 JUL 2013 07:45AM EST
- Manuscript Accepted: 13 JUL 2013
- Manuscript Revised: 24 JUN 2013
- Manuscript Received: 25 APR 2013
- cutaneous neoplasm;
- malignant melanoma
BRAF inhibition therapy, used to treat melanomas with BRAF mutations, is associated with both neoplastic and non-neoplastic cutaneous side effects including squamous cell carcinomas, warty dyskeratomas, verrucous keratoses, photosensitivity and widespread eruptions that present histopathologically as acantholytic dyskeratosis. We report a case of a patient undergoing BRAF inhibition therapy for disseminated melanoma with a V600E mutation who developed bilateral areolar leiomyomas, one of which was biopsied and the other of which resolved after discontinuation of vemurafenib therapy. To our knowledge, this is the first reported case of a mesenchymal neoplasm developing in association with BRAF inhibition therapy.